The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease ...

Merck (MRK) stock is in focus as the company secures $700M from Blackstone to advance cancer therapy sacituzumab tirumotecan ...

Merck MRK is scheduled to report third-quarter 2025 results on Oct. 30. Investors are likely to focus on the sales performance of its blockbuster cancer drug, Keytruda. The drug accounted for more ...

Blackstone Life Sciences agreed to give Merck $700 million to support its development of an investigational cancer drug called sacituzumab tirumotecan in exchange for low-to-mid-single-digit royalties ...

Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

The combination of Merck's Welireg and Eisai's Lenvima has not yet shown statistical significance in extending overall ...

Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

Five top-selling drugs, in some cases, are costing Americans thousands in out of pocket expenses weekly and monthly. Here's ...

Merck also lowered revenue guidance for 2025. The stock for pharmaceutical giant Merck (NYSE: MRK) was trading down more than ...

German diversified group Merck KGaA is preparing to put its pigments business up for sale to fund investments at its drugs ...